Harvard Bioscience (HBIO) Acquisitions (2010 - 2018)

Harvard Bioscience (HBIO) reported Acquisitions of $540000.0 for Q4 2018, down 9.24% quarter-over-quarter from $595000.0 in Q2 2018.

Harvard Bioscience (HBIO) Acquisitions (2010 - 2018) Analysis & Trends

Harvard Bioscience (HBIO) has 6 years of Acquisitions data on file, last reported at $540000.0 in Q4 2018.

Acquisitions for Q4 2018 came in at $540000.0, changed N/A year-over-year; the trailing twelve-month figure through Sep 2019 was $540000.0 (down 99.21% YoY), and the FY2018 annual result was $68.5 million, changed N/A from the prior year.
Acquisitions eased to $540000.0 in Q4 2018 per HBIO's latest filing, from $595000.0 in the prior quarter.
Over five years, Acquisitions peaked at $67.4 million in Q1 2018 and troughed at $540000.0 in Q4 2018.
A 3-year average of $17.1 million and a median of $4.5 million in 2015 frame the typical range for Acquisitions.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Acquisitions (Qtr)
1	Intuitive Surgical	148.09 Bn	143.69 Bn	1.83 Bn	528.20 Mn
2	Becton Dickinson	41.00 Bn	39.99 Bn	2.15 Bn	-
3	Medline	30.38 Bn	36.22 Bn	1.84 Bn	-
4	Resmed	28.22 Bn	26.56 Bn	890.98 Mn	24.88 Mn
5	West Pharmaceutical Services	23.72 Bn	23.19 Bn	296.40 Mn	-
6	Solventum	13.33 Bn	13.33 Bn	1.10 Bn	-
7	Cooper Companies	13.12 Bn	12.99 Bn	735.40 Mn	-
8	Align Technology	12.86 Bn	11.80 Bn	736.59 Mn	18.96 Mn
9	Baxter International	10.51 Bn	8.47 Bn	891.00 Mn	-
10	Harvard Bioscience	26.17 Mn	19.07 Mn	12.24 Mn	-

Download Data